Is oral mucositis occurring during chemotherapy for esophageal cancer patients correctly judged? EPOC observational cohort study

Yoshihiro Tanaka; Takao Ueno; Naoya Yoshida; Yasunori Akutsu; Hiroya Takeuchi; Hideo Baba; Hisahiro Matsubara; Yuko Kitagawa; Kazuhiro Yoshida

doi:10.21873/anticanres.13616

Is oral mucositis occurring during chemotherapy for esophageal cancer patients correctly judged? EPOC observational cohort study

Yoshihiro Tanaka, Takao Ueno, Naoya Yoshida, Yasunori Akutsu, Hiroya Takeuchi, Hideo Baba, Hisahiro Matsubara, Yuko Kitagawa, Kazuhiro Yoshida

Vice-President

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Abstract

Background/Aim: Oral mucositis (OM) is one of the frequent adverse events experienced by patients receiving chemotherapy. Most diagnoses of OM are based on complaints from patients. The aim of this study was to develop a tool to diagnose OM accurately. Materials and Methods: A central review system (CRS) was created to allow judgment when the patient background is completely unknown. The primary endpoint was the rate of grade 2 or higher OM, and the secondary endpoint was the difference in grade between each institution’s clinician judgement and that of the CRS. Results: In total, 53 patients were registered from four institutions. CRS successfully detected grade 2 or higher OM in 16 (30.2%) of the 53 patients. The detection rate of all grades of OM was 41.5% (22 of 53 patients) by each institution’s clinician judgement and 84.9% (45 of 53 patients) by CRS judgement (p<0.0001). Conclusion: OM during chemotherapy may be underestimated.

Original language	English
Pages (from-to)	4441-4448
Number of pages	8
Journal	Anticancer research
Volume	39
Issue number	8
DOIs	https://doi.org/10.21873/anticanres.13616
Publication status	Published - 2019

Keywords

Central review system
Chemotherapy
Esophageal carcinoma
Oral mucositis
Underestimation

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.21873/anticanres.13616

Cite this

@article{b0d7ecebc5f6498291dc0088ce2beee0,

title = "Is oral mucositis occurring during chemotherapy for esophageal cancer patients correctly judged? EPOC observational cohort study",

abstract = "Background/Aim: Oral mucositis (OM) is one of the frequent adverse events experienced by patients receiving chemotherapy. Most diagnoses of OM are based on complaints from patients. The aim of this study was to develop a tool to diagnose OM accurately. Materials and Methods: A central review system (CRS) was created to allow judgment when the patient background is completely unknown. The primary endpoint was the rate of grade 2 or higher OM, and the secondary endpoint was the difference in grade between each institution{\textquoteright}s clinician judgement and that of the CRS. Results: In total, 53 patients were registered from four institutions. CRS successfully detected grade 2 or higher OM in 16 (30.2%) of the 53 patients. The detection rate of all grades of OM was 41.5% (22 of 53 patients) by each institution{\textquoteright}s clinician judgement and 84.9% (45 of 53 patients) by CRS judgement (p<0.0001). Conclusion: OM during chemotherapy may be underestimated.",

keywords = "Central review system, Chemotherapy, Esophageal carcinoma, Oral mucositis, Underestimation",

author = "Yoshihiro Tanaka and Takao Ueno and Naoya Yoshida and Yasunori Akutsu and Hiroya Takeuchi and Hideo Baba and Hisahiro Matsubara and Yuko Kitagawa and Kazuhiro Yoshida",

note = "Funding Information: This study was partly supported by grants from the clinical trial program for cancer 2016 in the Japan Society of Clinical Oncology and was partly funded by EA Pharma Co., Ltd., Tokyo, Japan. The Authors would like to thank Rise Japan for providing editorial assistance and Meditrix K.K. for analyzing the data. Publisher Copyright: {\textcopyright} 2019 International Institute of Anticancer Research. All rights reserved.",

year = "2019",

doi = "10.21873/anticanres.13616",

language = "English",

volume = "39",

pages = "4441--4448",

journal = "Anticancer research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "8",

}

TY - JOUR

T1 - Is oral mucositis occurring during chemotherapy for esophageal cancer patients correctly judged? EPOC observational cohort study

AU - Tanaka, Yoshihiro

AU - Ueno, Takao

AU - Yoshida, Naoya

AU - Akutsu, Yasunori

AU - Takeuchi, Hiroya

AU - Baba, Hideo

AU - Matsubara, Hisahiro

AU - Kitagawa, Yuko

AU - Yoshida, Kazuhiro

N1 - Funding Information: This study was partly supported by grants from the clinical trial program for cancer 2016 in the Japan Society of Clinical Oncology and was partly funded by EA Pharma Co., Ltd., Tokyo, Japan. The Authors would like to thank Rise Japan for providing editorial assistance and Meditrix K.K. for analyzing the data. Publisher Copyright: © 2019 International Institute of Anticancer Research. All rights reserved.

PY - 2019

Y1 - 2019

N2 - Background/Aim: Oral mucositis (OM) is one of the frequent adverse events experienced by patients receiving chemotherapy. Most diagnoses of OM are based on complaints from patients. The aim of this study was to develop a tool to diagnose OM accurately. Materials and Methods: A central review system (CRS) was created to allow judgment when the patient background is completely unknown. The primary endpoint was the rate of grade 2 or higher OM, and the secondary endpoint was the difference in grade between each institution’s clinician judgement and that of the CRS. Results: In total, 53 patients were registered from four institutions. CRS successfully detected grade 2 or higher OM in 16 (30.2%) of the 53 patients. The detection rate of all grades of OM was 41.5% (22 of 53 patients) by each institution’s clinician judgement and 84.9% (45 of 53 patients) by CRS judgement (p<0.0001). Conclusion: OM during chemotherapy may be underestimated.

AB - Background/Aim: Oral mucositis (OM) is one of the frequent adverse events experienced by patients receiving chemotherapy. Most diagnoses of OM are based on complaints from patients. The aim of this study was to develop a tool to diagnose OM accurately. Materials and Methods: A central review system (CRS) was created to allow judgment when the patient background is completely unknown. The primary endpoint was the rate of grade 2 or higher OM, and the secondary endpoint was the difference in grade between each institution’s clinician judgement and that of the CRS. Results: In total, 53 patients were registered from four institutions. CRS successfully detected grade 2 or higher OM in 16 (30.2%) of the 53 patients. The detection rate of all grades of OM was 41.5% (22 of 53 patients) by each institution’s clinician judgement and 84.9% (45 of 53 patients) by CRS judgement (p<0.0001). Conclusion: OM during chemotherapy may be underestimated.

KW - Central review system

KW - Chemotherapy

KW - Esophageal carcinoma

KW - Oral mucositis

KW - Underestimation

UR - http://www.scopus.com/inward/record.url?scp=85070696345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070696345&partnerID=8YFLogxK

U2 - 10.21873/anticanres.13616

DO - 10.21873/anticanres.13616

M3 - Article

C2 - 31366542

AN - SCOPUS:85070696345

SN - 0250-7005

VL - 39

SP - 4441

EP - 4448

JO - Anticancer research

JF - Anticancer research

IS - 8

ER -

Is oral mucositis occurring during chemotherapy for esophageal cancer patients correctly judged? EPOC observational cohort study

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this